ClinicalTrials.gg
CompletedNCT00687245Updated Jun 11, 2008

Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)

A Phase 1 interventional study of esomeprazole magnesium in Endoscopically-Proven GERD and Reflux, sponsored by AstraZeneca. Completed. Open to participants aged 1 Year to 11 Years. Per ClinicalTrials.gov, last updated 2008-06-11.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
1 Year to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.

Enrollment
51st of 66
40 · median 125
Started
2006
with 12 others
Phase 1
6 of 67
none open now
Registered
43rd of 67
by date
Lead sponsor
36 of 67
AstraZeneca

Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 51st largest by enrollment of the 66 interventional ones that give a count, is one of 13 that started in 2006, is one of 6 in phase 1, and was the 43rd registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 1 Year to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing esomeprazole in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The purpose of this study is to determine the area under the plasma concentration-time curve (AUC) of esomeprazole after single oral doses of 5 mg, 10 mg or 20 mg esomeprazole in pediatric patients 1 to 11 years-old inclusive with endoscopically-proven GERD.

03

Conditions studied

  • Endoscopically-Proven GERD
  • Reflux

Keywords

  • children
  • reflux
  • GERD
  • pediatric
04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be able to take solid or bland food (eg, applesauce).
  • Patients must weigh at least 8 kg and at the investigator's discretion be able to undergo extraction of an adequate volume of blood.
  • The patient's weight for height percentile should be less than the 90th percentile and/or the must be between the 5th and 85th percentile for age.
  • Patients must be diagnosed with endoscopically-proven GERD

Exclusion criteria

Exclusion Criteria:

  • Use of any other compound or participation in another clinical trial within 28 days prior to the screening visit.
  • History or presence of gastrointestinal, hepatic or renal disease or other conditions that could interfere with absorption, distribution, metabolism or excretion of esomeprazole.
  • Unstable diabetes mellitus or history of seizure disorder.
  • Any acute or chronic illness or a medical history, which in the opinion of the investigator and/or sponsor, could compromise the patient's safety or successful participation in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    1

    esomeprazole magnesium 5 mg, weight 8 kg to \< 20kg

    Drug: esomeprazole magnesium

  • Experimental
    2

    esomeprazole magnesium 10 mg, weight 8 kg to \< 20kg

    Drug: esomeprazole magnesium

  • Experimental
    3

    esomeprazole magnesium 10 mg, weight \> 20 kg

    Drug: esomeprazole magnesium

  • Experimental
    4

    esomeprazole magnesium 20 mg, weight \> 20 kg

    Drug: esomeprazole magnesium

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve (AUC) of esomeprazole after single oral doses of 5 mg, 10 mg and 20 mg esomeprazole in pediatric patients 1 to 11 years old inclusive with endoscopically-proven GERD.

    Time frame: Day 1

Secondary outcomes

  1. The AUC(0-t), Cmax, tmax, and apparent volume of distribution during terminal phase (Vλz/F) of esomeprazole after single oral doses of 5 mg, 10 mg and 20 mg esomeprazole in pediatric patients 1 to 11 years-old inclusive with endoscopically-proven GERD.

    Time frame: Day 1

  2. AUC, AUC(0-t), Cmax, tmax, t1/2λz of the 5-hydroxy and sulphone metabolites of esomeprazole after a single oral dose of 5 mg, 10 mg, and 20 mg esomeprazole in pediatric patients 1 to 11 years-old inclusive with endoscopically-proven GERD.

    Time frame: Day 1

  3. Safety and tolerability after a single oral dose of esomeprazole in pediatric patients 1 to 11 years old inclusive with endoscopically- proven GERD.

    Time frame: Day 1, Day 15

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Earp JC, Mehrotra N, Peters KE, Fiorentino RP, Griebel D, Lee SC, Mulberg A, Rohss K, Sandstrom M, Taylor A, Tornoe CW, Wynn EL, Van der Walt JS, Garnett C. Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response. J Pediatr Gastroenterol Nutr. 2017 Sep;65(3):272-277. doi: 10.1097/MPG.0000000000001467. PubMed 27875488 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2008
First posted
May 30, 2008
Start
Aug 2006
Primary completionActual
May 2008
CompletionActual
May 2008
Last update
Jun 11, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00687245
Lead sponsor
AstraZeneca
First posted
May 30, 2008
Start date
Aug 2006
Primary completion
May 2008
Completion
May 2008
Last update
Jun 11, 2008

Study contacts

Marta Illueca
study director · AstraZeneca
Lynne Durborow
study chair · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion